| Autor: |
Sadhewa A; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia., Cassidy-Seyoum S; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia., Acharya S; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia., Devine A; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne 3010, Australia.; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne 3010, Australia., Price RN; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia.; Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX1 2JD, UK., Mwaura M; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia., Thriemer K; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia., Ley B; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin 0810, Australia. |
| Abstrakt: |
Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8-aminoquinoline drugs are crucial for the complete removal of the parasite from the human host (radical cure). While well tolerated in most recipients, 8-aminoquinolines can cause severe haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. G6PD deficiency is one of the most common enzymopathies worldwide; therefore, the WHO recommends routine testing to guide 8-aminoquinoline based treatment for vivax malaria whenever possible. In practice, this is not yet implemented in most malaria endemic countries. This review provides an update of the characteristics of the most used G6PD diagnostics. We describe the current state of policy and implementation of routine point-of-care G6PD testing in malaria endemic countries and highlight key knowledge gaps that hinder broader implementation. Identified challenges include optimal training of health facility staff on point-of-care diagnostics, quality control of novel G6PD diagnostics, and culturally appropriate information and communication with affected communities around G6PD deficiency and implications for treatment. |
